FAQ: What's Next for Pharma Traceability After DSCSA

Why outdated paper prescribing information is creating unnecessary cost, complexity and friction across a modern pharmaceutical supply chain.

Episode 4 of Supply Chain Signal examines PhRMA’s legal challenge to CMS’ GLOBE model and whether manufacturers can lower costs, expand U.S. production and strengthen supply chain resilience all at once.

As organized groups add impersonation and email fraud to hijackings and trailer thefts, every handoff between shipping partners has become a point of exposure.

The rule targets PBMs, but rebate, price protection and formulary deals they strike with drugmakers will be disclosed to plan fiduciaries and open to audit.

DOL's final rule requires PBMs to disclose rebates and formulary incentives to large self-insured plans for plan years beginning on or after July 1, 2027.

In this week’s Pharma Pulse, GoodRx expands an employer offering built on manufacturer pricing for GLP-1 obesity drugs, a federal judge declines to block Lilly’s comparative Zepbound ads, and the PBM industry’s trade group turns the vertical integration debate toward drug wholesalers.

At LogiPharma USA 2026, Mark Talens explains how end-to-end visibility lets pharma see its value chain across functions, and where supply chain monitoring is headed next.

BMS’s Kevin Cook explains why digital capability is becoming a must-have for strategic CMO partners and why the next phase starts with the basics.